BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29955482)

  • 1. Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion.
    Boggs DL; Peckham A; Boggs AA; Ranganathan M
    Ment Health Clin; 2016 Nov; 6(6):277-284. PubMed ID: 29955482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
    Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
    J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
    Meyer T; Funke A; Münch C; Kettemann D; Maier A; Walter B; Thomas A; Spittel S
    BMC Neurol; 2019 Sep; 19(1):222. PubMed ID: 31493784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Δ
    Silveira MM; Adams WK; Morena M; Hill MN; Winstanley CA
    J Psychiatry Neurosci; 2017 Mar; 42(2):131-138. PubMed ID: 28245177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
    Niesink RJ; Rigter S; Koeter MW; Brunt TM
    Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
    Arnold JC; Boucher AA; Karl T
    Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
    Fasinu PS; Phillips S; ElSohly MA; Walker LA
    Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol in medical marijuana: Research vistas and potential opportunities.
    Rong C; Lee Y; Carmona NE; Cha DS; Ragguett RM; Rosenblat JD; Mansur RB; Ho RC; McIntyre RS
    Pharmacol Res; 2017 Jul; 121():213-218. PubMed ID: 28501518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
    Nadulski T; Sporkert F; Schnelle M; Stadelmann AM; Roser P; Schefter T; Pragst F
    J Anal Toxicol; 2005; 29(8):782-9. PubMed ID: 16356335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain.
    Casey SL; Vaughan CW
    Medicines (Basel); 2018 Jul; 5(3):. PubMed ID: 29966400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
    Malone DT; Jongejan D; Taylor DA
    Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Yang Y; Lewis MM; Bello AM; Wasilewski E; Clarke HA; Kotra LP
    Cannabis Cannabinoid Res; 2017; 2(1):274-281. PubMed ID: 29098190
    [No Abstract]   [Full Text] [Related]  

  • 19. A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis.
    Berman P; Futoran K; Lewitus GM; Mukha D; Benami M; Shlomi T; Meiri D
    Sci Rep; 2018 Sep; 8(1):14280. PubMed ID: 30250104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cannabidiol (CBD) on Δ⁹-tetrahydrocannabinol (THC) self-administration in male and female Long-Evans rats.
    Wakeford AGP; Wetzell BB; Pomfrey RL; Clasen MM; Taylor WW; Hempel BJ; Riley AL
    Exp Clin Psychopharmacol; 2017 Aug; 25(4):242-248. PubMed ID: 28682102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.